These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
159 related items for PubMed ID: 15033255
1. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, Haass M, Schraeder R, Strasser RH. Eur Heart J; 2004 Mar; 25(5):424-30. PubMed ID: 15033255 [Abstract] [Full Text] [Related]
2. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism. Spies C, Timmermanns I, Reissmann U, van Essen J, Schräder R. Catheter Cardiovasc Interv; 2008 Feb 15; 71(3):390-5. PubMed ID: 18288745 [Abstract] [Full Text] [Related]
3. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. Chatterjee T, Petzsch M, Ince H, Rehders TC, Körber T, Weber F, Schneider H, Auf der Maur C, Nienaber CA. J Interv Cardiol; 2005 Jun 15; 18(3):173-9. PubMed ID: 15966921 [Abstract] [Full Text] [Related]
4. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Spies C, Strasheim R, Timmermanns I, Schraeder R. Eur Heart J; 2006 Feb 15; 27(3):365-71. PubMed ID: 16254007 [Abstract] [Full Text] [Related]
7. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism. Cifarelli A, Musto C, Parma A, Pandolfi C, Pucci E, Fiorilli R, De Felice F, Nazzaro MS, Violini R. Int J Cardiol; 2010 Jun 11; 141(3):304-10. PubMed ID: 19178959 [Abstract] [Full Text] [Related]
8. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder. Kutty S, Brown K, Asnes JD, Rhodes JF, Latson LA. Am J Cardiol; 2008 May 15; 101(10):1487-92. PubMed ID: 18471463 [Abstract] [Full Text] [Related]
9. Comparison of contemporary devices used for transcatheter patent foramen ovale closure. Spies C, Reissmann U, Timmermanns I, Schräder R. J Invasive Cardiol; 2008 Sep 15; 20(9):442-7. PubMed ID: 18762672 [Abstract] [Full Text] [Related]
10. Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects. Silverman IE, Kiernan FJ, Kelsey AM, Brakoniecki JJ, Kazi FA, Dougherty JE, Boden WE, McKay RG. Conn Med; 2003 Mar 15; 67(3):135-44. PubMed ID: 12687787 [Abstract] [Full Text] [Related]
11. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder. Silvestry FE, Naseer N, Wiegers SE, Hirshfeld JW, Herrmann HC. Catheter Cardiovasc Interv; 2008 Feb 15; 71(3):383-7. PubMed ID: 18288733 [Abstract] [Full Text] [Related]
12. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Harms V, Reisman M, Fuller CJ, Spencer MP, Olsen JV, Krabill KA, Gray WA, Jesurum JT. Am J Cardiol; 2007 May 01; 99(9):1312-5. PubMed ID: 17478164 [Abstract] [Full Text] [Related]
13. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure. Dubiel M, Bruch L, Liebner M, Schmehl I, Winkelmann A, Rux S, Sonntag S, Wulff H, Grad MO, Kleber FX. J Interv Cardiol; 2007 Aug 01; 20(4):275-81. PubMed ID: 17680857 [Abstract] [Full Text] [Related]
14. Impact of occluder device type on success of percutaneous closure of atrial septal defects--a medium-term follow-up study. Becker M, Frings D, Schröder J, Ocklenburg C, Mühler E, Hoffmann R, Franke A, Lepper W. J Interv Cardiol; 2009 Dec 01; 22(6):503-10. PubMed ID: 19821880 [Abstract] [Full Text] [Related]